

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ocrelizumab for treating primary progressive multiple sclerosis [ID938]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No equality issues were raised during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

The company provided clinical data from a subgroup limited to people aged 50 years or younger and modelled the cost effectiveness of ocrelizumab for this subgroup.

The committee was aware that the marketing authorisation does not specify an age threshold for treatment. It concluded that, in the absence of a clear biological rationale to exclude data from patients aged 50 to 55 years, it was not appropriate to define an age limit in this guidance (see section 3.6 of the ACD).

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No equality issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Not applicable

Approved by Associate Director (name): Melinda Goodall.....

Date: 15.06.2018

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Several consultation responses stated that the draft recommendation discriminated against people with primary progressive multiple sclerosis, because ocrelizumab has been recommended for use to treat relapsing-remitting multiple sclerosis by NICE in a separate appraisal. In the final appraisal decision for this topic, ocrelizumab is recommended, within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the recommendations apply to the full population in the marketing authorisation.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, the recommendations apply to the full population in the marketing authorisation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified

in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No, the recommendations apply to the full population in the marketing authorisation.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Not applicable.

Approved by Associate Director (name):Nicole Elliott.....

Date: 18/04/2019